Skip to main content
Top
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology 6/2020

Open Access 01-06-2020 | Retinal Diseases | Review Article

Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic

Authors: Jean-François Korobelnik, Anat Loewenstein, Bora Eldem, Antonia M. Joussen, Adrian Koh, George N. Lambrou, Paolo Lanzetta, Xiaoxin Li, Monica Lövestam-Adrian, Rafael Navarro, Annabelle A. Okada, Ian Pearce, Francisco J. Rodríguez, David T. Wong, Lihteh Wu

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 6/2020

Login to get access

Abstract

Purpose

There is an urgent need to address how to best provide ophthalmic care for patients with retinal disease receiving intravitreal injections with anti-vascular endothelial growth factor agents during the ongoing global COVID-19 pandemic. This article provides guidance for ophthalmologists on how to deliver the best possible care for patients while minimizing the risk of infection.

Methods

The Vision Academy’s Steering Committee of international retinal disease experts convened to discuss key considerations for managing patients with retinal disease during the COVID-19 pandemic. After reviewing the existing literature on the issue, members put forward recommendations that were systematically refined and voted on to develop this guidance.

Results

The considerations focus on the implementation of steps to minimize the exposure of patients and healthcare staff to COVID-19. These include the use of personal protective equipment, adherence to scrupulous hygiene and disinfection protocols, pre-screening to identify symptomatic patients, and reducing the number of people in waiting rooms. Other important measures include triaging of patients to identify those at the greatest risk of irreversible vision loss and prioritization of treatment visits over monitoring visits where possible. In order to limit patient exposure, ophthalmologists should refrain from using treatment regimens that require frequent monitoring.

Conclusion

Management of patients with retinal disease receiving intravitreal injections during the COVID-19 pandemic will require adjustment to regular clinical practice to minimize the risk of exposure of patients and healthcare staff, and to prioritize those with the greatest medical need. The safety of patients and healthcare staff should be of paramount importance in all decision-making.
Literature
17.
go back to reference Korobelnik JF, Loewenstein A, on behalf of the Vision Academy (2020) Communicating with patients with nAMD and their families during the COVID-19 pandemic. Graefes Arch Clin Exp Ophthalmol [in press] Korobelnik JF, Loewenstein A, on behalf of the Vision Academy (2020) Communicating with patients with nAMD and their families during the COVID-19 pandemic. Graefes Arch Clin Exp Ophthalmol [in press]
18.
go back to reference Bressler NM, Beaulieu WT, Glassman AR, Blinder KJ, Bressler SB, Jampol LM, Melia M, Wells JA 3rd, for the Diabetic Retinopathy Clinical Research Network (2018) Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol 136:257–269. https://doi.org/10.1001/jamaophthalmol.2017.6565CrossRefPubMedPubMedCentral Bressler NM, Beaulieu WT, Glassman AR, Blinder KJ, Bressler SB, Jampol LM, Melia M, Wells JA 3rd, for the Diabetic Retinopathy Clinical Research Network (2018) Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol 136:257–269. https://​doi.​org/​10.​1001/​jamaophthalmol.​2017.​6565CrossRefPubMedPubMedCentral
19.
go back to reference Schmidt-Erfurth U, Lang GE, Holz FG, Schlingemann RO, Lanzetta P, Massin P, Gerstner O, Bouazza AS, Shen H, Osborne A, Mitchell P, RESTORE Extension Study Group (2014) Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology 121:1045–1053. https://doi.org/10.1016/j.ophtha.2013.11.041CrossRefPubMed Schmidt-Erfurth U, Lang GE, Holz FG, Schlingemann RO, Lanzetta P, Massin P, Gerstner O, Bouazza AS, Shen H, Osborne A, Mitchell P, RESTORE Extension Study Group (2014) Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology 121:1045–1053. https://​doi.​org/​10.​1016/​j.​ophtha.​2013.​11.​041CrossRefPubMed
Metadata
Title
Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic
Authors
Jean-François Korobelnik
Anat Loewenstein
Bora Eldem
Antonia M. Joussen
Adrian Koh
George N. Lambrou
Paolo Lanzetta
Xiaoxin Li
Monica Lövestam-Adrian
Rafael Navarro
Annabelle A. Okada
Ian Pearce
Francisco J. Rodríguez
David T. Wong
Lihteh Wu
Publication date
01-06-2020
Publisher
Springer Berlin Heidelberg
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 6/2020
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-020-04703-x

Other articles of this Issue 6/2020

Graefe's Archive for Clinical and Experimental Ophthalmology 6/2020 Go to the issue